Home World News FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with... World News FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency By Ogkologos - February 18, 2026 406 0 Facebook Twitter Google+ Pinterest WhatsApp Patients should be tested for genetic variants of DPYD prior to initiating treatment Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Dunkin’ Customer Surprises Homeless Employee With Fully Furnished Home December 15, 2021 Cancer in My Community: Overcoming Delays in Care for Children With... July 6, 2023 EMA Recommends Granting a Marketing Authorisation for Melphalan October 1, 2020 Teen With Cancer On Dream Trip To NASA Gets Surprise Call... May 9, 2019 Load more HOT NEWS Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for... Breaking the silence: when cancer steals your voice Scientists Discover How Air Pollution May Trigger Lung Cancer in Never-Smokers... Long-Term Efficacy of Single-Agent Neoadjuvant/Adjuvant PD1 Blockade for Resectable Cutaneous Melanoma...
